In addition, melatonin treatment promoted a reduction in serum insulin and low-density lipoprotein-cholesterol (LDL-c) levels, a reduction in homeostasis model assessment of insulin resistance (HOMA-IR), and an increase in peroxisome proliferator-activated receptor gamma (PPARγ) and low-density lipoprotein (LDL)-receptor gene expression. The gene discussed is PPARG; the disease is Insulin resistance.